Navigation Links
Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant. Patients received blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to five treatment cycles. Patients received a continuous intravenous infusion of blinatumomab at an initial dose of five or 15 micrograms/m2 per day, escalating to 30 micrograms for the remainder of the treatment. The primary endpoint of the study was the rate of complete remission (CR) and complete remission with partial hematologic recovery (CRh*). Secondary endpoints included molecular response rate, duration of response and overall survival. All 36 patients were evaluable for efficacy and safety.

Twenty-six of the 36 patients (72%) treated with blinatumomab across all of the tested doses and schedules achieved a CR/CRh*. All but two patients achieved a molecular response, meaning there was no evidence of leukemic cells by polymerase chain reaction. The most common adverse events were pyrexia, headache and tremor. Medically important safety events were reversible cytokine release syndrome and CNS adverse events.

At the time of the analysis, median survival was 9.0 (8.2, 15.8) months with a median follow-up period of 10.7 months. The median duration of response in the 26 patients who responded to treatment was 8.9 months.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th Congress of EHA is taking place in Amsterdam. Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases (in the production) of blood and their treatments. The latest data on research and developments within the wide spectrum of hematology are presented.

 


'/>"/>
SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
6. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
7. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
8. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
9. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
10. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
11. GeneLink Reports First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... ... August 11, 2017 , ... ... and, in particular, more natural alternatives to synthetic ingredients,” said Matt Hundt, President ... Wave, with the established manufacturing presence and know-how of Biorigin will allow us ...
(Date:8/10/2017)... Philadelphia, PA (PRWEB) , ... August 09, 2017 ... ... back to the classroom next week-- as students. From August 14th through the ... Institute. The institute, which debuted in the summer of 2016, provides Philadelphia-based middle ...
(Date:8/10/2017)... ... August 09, 2017 , ... Each year in the United States ... enough to live an independent lifestyle and, even worse, the one-year mortality rate is ... doctors at the University of California Davis Medical Center (Sacramento) and Second Xiangya Hospital ...
(Date:8/10/2017)... California, USA (PRWEB) , ... August 09, 2017 ... ... has partnered with four international biomedical optics laboratories — the Wellman Center for ... Hospital, Medical Laser Center Lübeck and the Beckman Laser Institute at University of ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
Breaking Biology News(10 mins):